RNA-Sequencing of B-Lymphoblastic Leukemia with Glucocorticoids and PI3K Delta Inhibition
Demographics (4)
- AGE - Subject age at enrollment (phv00510405.v1.p1)
- AGE_ONSET - Subject age at initial diagnosis of B-lymphoblastic leukemia (phv00510406.v1.p1)
- COLLECTION_AGE - Age sample was collected (phv00510415.v1.p1)
- SEX - Biological sex (phv00510401.v1.p1)
Other (16)
- ANALYTE_TYPE - Analyte Type (phv00510411.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00510410.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00510400.v1.p1)
- CYTOGENETIC_CATEGORY - Cytogenetic feature of sample (phv00510414.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00510413.v1.p1)
- IS_TUMOR - Tumor status (phv00510412.v1.p1)
- NEW_RELAPSED_TUMOR - Newly diagnosed or relapsed tumor (phv00510416.v1.p1)
- SAMPLE_ID - Sample ID (phv00510409.v1.p1)
- SAMPLE_ID - Sample ID (phv00510403.v1.p1)
- SAMPLE_TREATMENT - Type of in vitro treatment for sample (phv00510418.v1.p1)
- SUBJECT_ID - Subject ID (phv00510404.v1.p1)
- SUBJECT_ID - Subject ID (phv00510399.v1.p1)
- SUBJECT_ID - Subject ID (phv00510402.v1.p1)
- TUMOR_EOI_MRD - Tumor end of induction minimal residual disease status (phv00510408.v1.p1)
- TUMOR_RISK_GROUP - NCI risk group classification of tumor at diagnosis (phv00510407.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00510417.v1.p1)